Questionnaire - Vinglyn - DAY - Diabetes Awareness & You

We value your opinion. Kindly go through few important questions and share your views on it.

Name

Email ID

Phone No

City

State

Pin Code

PAN

The above information is correct to best of knowledge & I do hereby give my consent to use the information of this survey for research work in future.

1. In your opinion, why does the management of type 2 diabetes pose a unique and complex health challenge in India?

a) Burden is higher than in developed countries

b) Burden may be masked by inadequate reporting

c) Substantially lower number of diabetes registries available

d) All of the above

2. Which factors are associated with development of diabetes in the thin Indian phenotype patient?

a) Early age of T2DM onset

b) Early decline in beta cell mass

c) Higher insulin resistance

d) Higher carbohydrateintake and physical inactivity

3. In your opinion, which are the patient-centric factors responsible for poor glycemic control in India?

a) Non-compliance to lifestyle measures

b) Poor frequency of self-monitoring of blood glucose levels

c) Poor drug adherence

d) Low disease awareness

e) All of the above

4. In your opinion, what are the disease-centric factors responsible for poor glycemic control in India?

a) Obesity

b) Longer duration of diabetes

c) Hypertension

d) Requirement for diverse therapeutic options for the individualization of care (personalized medicine)

5. When do you usually initiate Vildagliptin in the Management of T2DM in your clinical practice?

a) As monotherapy in Newly diagnosed T2DM

b) As an add-on to patients uncontrolled on metformin monotherapy

c) As FDC with Metformin with high baseline HbA1c

d) As an add-on to patients uncontrolled on metformin-based combinations

6. When do you initiate Dapagliflozin in the Management of T2DM in your clinical practice?

a) As monotherapy in newly diagnosed T2DM

b) As an add-on to patients uncontrolled on metformin monotherapy

c) As FDC with Metformin with high baseline HbA1c

d) As an add-on to patients uncontrolled on metformin-based combinations

7. In your clinical practice how frequently do you see patients with high HbA1C levels who require FDC of vildagliptin-dapagliflozin?

a) <5 patients per month

b) 5-10patients per month

c) 10-20patients per month

d) >20patients per month

8. In your opinion which sequence of administering antidiabetic drug will be more effective ?

a) Vildagliptin followed by Dapagliflozin

b) Dapagliflozin followed by Vildagliptin

c) Molecule can be used in any order

9. In your opinion which category of patients can be benefitted with a FDC of Vildagliptin & Dapagliflozin?

a) Treatment naïve patients

b) As an add-on to patients uncontrolled on vildagliptin or dapagliflozin monotherapy

c) As an add-on to patients uncontrolled on Metformin monotherapy

d) As an alternative add-on to patients uncontrolled on metformin-based combinations with other DPP4 Inhibitors/SGLT2 Inhibitors

e) As an alternative add-onto patients uncontrolled on metformin-based combinations other than DPP4 Inhibitors/SGLT2 Inhibitors

f) All of the above

10. Is the use of FDC of SGLT2i + DPP4i more safe than sequential addition of SGLT2i to DPP4i Therapy?

a) YES

b) NO

11. Along with vildagliptin 100 mg SR formulation what strength of Dapagliflozin (5/10) mg is more preferred as FDC in clinical practice?

a) 5 mg

b) 10 mg

c) Both will be useful as per patient’s requirement

12. In your opinion FDC of SGLT2i + DPP4i is a suitable option for Indian T2D patients, because of _______

a) Safer, rapid, and sustained glycemic control

b) Improves both insulin resistance and beta cell function

c) Helps reduce body weight and blood pressure (extra-glycemic benefits)

d) Reduces pill burden (improved adherence and compliance)

e) Reduction in occurrence of hypoglycemia or weight gain

f) All of the above

13. Evidence suggests that time in range (TIR) complements HbA1c as a parameter of glycemic control, with higher TIR associated with better clinical outcomes. In your clinical experience, do DPP4i and SGLT2i have beneficial effects on TIR?

a) YES

b) NO

Questionnaire – Vinglyn

Leave a Reply Cancel reply